Patent ID: 10775389

Abstract:
The present invention relates to a method for identifying a subject, which has peripartum cardiomyopathy (PPCM) or which has a risk for developing PPCM, wherein the method comprises analyzing the amount and/or activity of plasminogen activator inhibitor-1 (PAI-1); and/or the genotype of the PAI-1 gene. The invention also relates to an inhibitor of PAI-1 for use in the treatment of PPCM. Also a method of treating PPCM in a subject in need of such a treatment, wherein said method comprises administering to said subject an effective amount of an inhibitor of PAI-1 is comprised in the present invention. Moreover, the present invention further relates to the use of a binding molecule for identifying a subject, which has PPCM or which has a risk for developing PPCM, wherein said binding molecule specifically binds to PAI-1.